{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T18:41:14Z","timestamp":1784140874936,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,11,27]],"date-time":"2017-11-27T00:00:00Z","timestamp":1511740800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s00066-017-1239-1","type":"journal-article","created":{"date-parts":[[2017,11,27]],"date-time":"2017-11-27T09:02:10Z","timestamp":1511773330000},"page":"318-324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Oligometastases in prostate cancer","Oligometastasen bei Prostatakarzinom"],"prefix":"10.1007","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4590-1972","authenticated-orcid":false,"given":"Ren\u00e9","family":"Baumann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Koncz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Luetzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen","family":"Dunst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,27]]},"reference":[{"key":"1239_CR1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","volume":"42","author":"A Afshar-Oromieh","year":"2015","unstructured":"Afshar-Oromieh A, Avtzi E, Giesel FL et al (2015) The diagnostic value of PET\/CT imaging with the Ga-68-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42:197\u2013209","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1239_CR2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00259-013-2525-5","volume":"41","author":"A Afshar-Oromieh","year":"2014","unstructured":"Afshar-Oromieh A, Zechmann CM, Malcher A et al (2014) Comparison of PET imaging with a\u00a0Ga-68-labelled PSMA ligand and F\u201118-choline- based PET\/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 41:11\u201320","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1239_CR3","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/RLU.0000000000001197","volume":"41","author":"C Bluemel","year":"2016","unstructured":"Bluemel C, Krebs M, Polat B et al (2016) 68Ga-PSMA-PET\/CT in patients with biochemical prostate cancer recurrence and negative 18F-choline-PET\/CT. Clin Nucl Med 41:515\u2013521","journal-title":"Clin Nucl Med"},{"key":"1239_CR4","doi-asserted-by":"crossref","first-page":"225622","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S","volume":"82","author":"DG Bostwick","year":"1998","unstructured":"Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP (1998) Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a\u00a0study of 184 cases. Cancer 82:225622\u2013225661","journal-title":"Cancer"},{"key":"1239_CR5","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.eururo.2015.06.010","volume":"69","author":"L Budaus","year":"2016","unstructured":"Budaus L, Leyh-Bannurah SR, Salomon G et al (2016) Initial experience of 68Ga-PSMA PET\/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol 69:393\u2013396","journal-title":"Eur Urol"},{"key":"1239_CR6","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1007\/s00259-015-3078-6","volume":"42","author":"F Ceci","year":"2015","unstructured":"Ceci F, Uprimny C, Nilica B et al (2015) Ga-68-PSMA PET\/CT for restaging recurrent prostate cancer: which factors are associated with PET\/CT detection rate? Eur J Nucl Med Mol Imaging 42:1284\u20131294","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1239_CR7","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/pros.22956","volume":"75","author":"MO Demirkol","year":"2015","unstructured":"Demirkol MO, Acar O, Ucar B, Ramazanotlu SR, Satlican Y, Esen T (2015) Prostate-specific membrane antigen-based imaging in prostate cancer: impact on clinical decision making process. Prostate 75:748\u2013757","journal-title":"Prostate"},{"key":"1239_CR8","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s11307-015-0866-0","volume":"17","author":"M Dietlein","year":"2015","unstructured":"Dietlein M, Kobe C, Kuhnert G et al (2015) Comparison of [18F]DCFPyL and [68Ga]-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol 17:575\u2013584","journal-title":"Mol Imaging Biol"},{"key":"1239_CR9","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2967\/jnumed.115.154153","volume":"56","author":"M Eiber","year":"2015","unstructured":"Eiber M, Maurer T, Souvatzoglou M et al (2015) Evaluation of hybrid Ga-68-PSMA ligand PET\/CT in 248 patients with biochemical re-currence after radical prostatectomy. J\u00a0Nucl Med 56:668\u2013674","journal-title":"J Nucl Med"},{"key":"1239_CR10","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s00259-015-3206-3","volume":"43","author":"MT Freitag","year":"2016","unstructured":"Freitag MT, Radtke JP, Hadaschik BA et al (2016) Comparison of hybrid Ga-68-PSMA PET\/MRI and Ga-68-PSMA PET\/CT in the evaluation of lymph node and bone metastases of prostate cancer. Eur J Nucl Med Mol Imaging 43:70\u201383","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1239_CR11","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1007\/s00259-015-3106-6","volume":"42","author":"FL Giesel","year":"2015","unstructured":"Giesel FL, Fiedler H, Stefanova M et al (2015) PSMA PET\/CT with Glu-urea- Lys-(Ahx)-[Ga-68(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42:1794\u20131800","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1239_CR12","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.eururo.2015.12.051","volume":"70","author":"A Herlemann","year":"2016","unstructured":"Herlemann A, Wenter V, Kretschmer A et al (2016) 68Ga-PSMA positron emission tomography\/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer. Eur Urol 70:553\u2013555","journal-title":"Eur Urol"},{"key":"1239_CR13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00345-016-1860-0","volume":"35","author":"G Ingrosso","year":"2017","unstructured":"Ingrosso G, Trippa F, Maranzano E, Carosi A, Ponti E, Arcidiacono F, Draghini L, Di Murro L, Lancia A, Santoni R (2017) Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a\u00a0two-institution experience. World J Urol 35:45\u201349","journal-title":"World J Urol"},{"key":"1239_CR14","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/MNM.0000000000000290","volume":"36","author":"L Kabasakal","year":"2015","unstructured":"Kabasakal L, Demirci E, Ocak M et al (2015) Evaluation of PSMA PET\/CT imaging using a\u00a0Ga-68-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. Nucl Med Commun 36:582\u2013587","journal-title":"Nucl Med Commun"},{"key":"1239_CR15","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ijrobp.2010.11.054","volume":"82","author":"CR King","year":"2012","unstructured":"King CR, Brooks JD, Gill H et al (2012) Long-term outcomes from a\u00a0prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 82:877\u2013882","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1239_CR16","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.2967\/jnumed.115.160382","volume":"56","author":"JJ Morigi","year":"2015","unstructured":"Morigi JJ, Stricker PD, van Leeuwen PJ et al (2015) Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET\/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J\u00a0Nucl Med 56:1185\u20131190","journal-title":"J Nucl Med"},{"key":"1239_CR17","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.ijrobp.2016.01.032","volume":"95","author":"JL Muldermans","year":"2016","unstructured":"Muldermans JL, Romak LB, Kwon ED, Park SS, Olivier KR (2016) Stereotactic body radiation therapy for oligometastatic prostate cancer. Int J Radiat Oncol Biol Phys 95:696\u2013702","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1239_CR18","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.juro.2015.12.025","volume":"195","author":"M Perera","year":"2016","unstructured":"Perera M et al (2016) Sensitivity, specificity, and predictors of positive 68gallium-PSMA positron emission tomography compared to conventional imaging in lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J\u00a0Urol 195:1436\u20131443","journal-title":"J Urol"},{"key":"1239_CR19","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","volume":"70","author":"M Perera","year":"2016","unstructured":"Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, Bolton D, Lawrentschuk N (2016) Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol 70:926\u2013929","journal-title":"Eur Urol"},{"key":"1239_CR20","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2165\/00063030-200013060-00007","volume":"13","author":"EM Plut","year":"2000","unstructured":"Plut EM, Hinkle GH (2000) 111In-capromab pendetide: the evolution of prostate specific membrane antigen and the nuclear imaging of its 111In-labelled murine antibody in the evaluation of prostate cancer. BioDrugs 13:437\u2013447","journal-title":"BioDrugs"},{"issue":"Suppl 1","key":"1239_CR21","doi-asserted-by":"crossref","first-page":"S 84","DOI":"10.1016\/S0140-6736(16)32011-6","volume":"388","author":"S Qiu","year":"2016","unstructured":"Qiu S, Yang L, Deng L, Liu L, Han P, Wei Q (2016) Efficacy and safety of prostate-targeted local therapy in patients with newly diagnosed oligometastatic prostate cancer: a\u00a0systematic review and meta-analysis. Lancet 388(Suppl 1):S 84","journal-title":"Lancet"},{"key":"1239_CR22","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3:81\u201385","journal-title":"Clin Cancer Res"},{"key":"1239_CR23","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/bju.13397","volume":"117","author":"PJ Leeuwen van","year":"2016","unstructured":"van Leeuwen PJ, Stricker P, Hruby G, Kneebone A, Ting F, Thompson B, Nguyen Q, Ho B, Emmett L (2016) (68)Ga-PSMA has a\u00a0high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. BJU Int 117:732\u2013739","journal-title":"BJU Int"},{"issue":"Suppl 1","key":"1239_CR24","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J\u00a0Nucl Med 50(Suppl 1):122S\u2013150S","journal-title":"J. Nucl. Med."},{"key":"1239_CR25","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00259-015-3257-5","volume":"43","author":"C Zamboglou","year":"2016","unstructured":"Zamboglou C, Wieser G, Hennies S, Rempel I, Kirste S, Soschynski M, Rischke HC, Fechter T, Jilg CA, Langer M, Meyer PT, Bock M, Grosu AL (2016) MRI versus 68Ga-PSMA PET\/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer. Eur J Nucl Med Mol Imaging 43:889\u2013897","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00066-017-1239-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-017-1239-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-017-1239-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,26]],"date-time":"2018-03-26T05:58:17Z","timestamp":1522043897000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00066-017-1239-1"}},"subtitle":["Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT","Metabolisches Ansprechen in Follow-up-PSMA-PET\/CT nach hypofraktionierter bildgef\u00fchrter Strahlentherapie"],"short-title":[],"issued":{"date-parts":[[2017,11,27]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["1239"],"URL":"https:\/\/doi.org\/10.1007\/s00066-017-1239-1","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,27]]}}}